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SUMMARY
Sixty-nine patients with multiple myeloma diagnosed during a five year period
at the Belfast City Hospital were followed until death or for a minimum of one
year in a retrospective study ofsurvival. Although the patients were unselected,
survival data was found to be similar to results from trials in which patient
selection had occurred. Overall median survival was thirty-two months. Median
survival fell with advancing disease and was 47, 27 and 18 months for Durie
Salmon stages 1, 11 and /i1 respectively. Those patients presenting with a platelet
count of < 100 x 109/1 had a median survival ofeight months in contrast to
those with a platelet count .> 100 x 109/1 whose median survival was 36
months. Patients presenting in renal failure had a shorter median survival of
28 months compared to 46 months for those with normal renal function.
INTRODUCTION
Over the last 25 years a series of multicentre studies by the Medical Research
Council has shown a progressive improvement in the survival of patients with
multiple myeloma.1-4 This has been achieved through an increase in the intensity
of chemotherapeutic regimens and an improvement in supportive care. The
outcome of any trial will be affected bythe preselection ofpatients for the trial and
may often lead to apparently significant improvement in progress.5 The present
study describes the outcome for an unselected group of patients diagnosed and
treated atthis hospital during a five year period with follow-up to death, orfor one
to five years survival.
In 1990, the most recent yearforwhich accurate figures are available, 92 patients
were diagnosed as having multiple myeloma in Northern Ireland. (Northern
Ireland Leukaemia Research Fund data collection service).
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METHODS
Sixty-nine patients with multiple myeloma diagnosed in the Belfast City Hospital
between 1 January 1986 and 31 December 1990 were identified using the
records of bone marrow examination and protein biochemistry. Administration
of chemotherapy was supervised by the staff of the haematology department.
The clinical haematology charts of all the patients were analysed to determine
outcome. Laboratory findings utilised for diagnosis of myeloma included plasma
cell infiltration in the bone marrow greater than 5%, a paraprotein band in serum
or urine, and lytic bone lesions on skeletal radiography.
Patients were staged according to the Durie-Salmon classification.6 In stage I all
of the following are present - haemoglobin > 10 g/dl, normal serum calcium,
normal bone structure on X-ray (or a solitary plasmacytoma only) with low para-
protein production rates [lgG <60 g/l, IgA <30 g/l, urine lightchains <4 g/24
hours]. Stage III is defined by the presence of any one of the following - Hb
< 8-5 g/dl, serum calcium > 2-62 mmol/l, advanced bone lytic lesions, high
paraprotein production rates [IgG > 70 g/l, IgA > 50 g/l, urine light chains > 12
g/24 hours]. Stage II are those patients between I and II1. A further subclassific-
ation into subgroup a (serum creatinine < 176 ug/dl) or subgroup b (serum
creatinine .176 ug/dl) was also used (Table 1).
TABLE I
Stage and age ofpatients
Stage No Median age Age range
yr yr
la 23 (34%) 68 39 - 83
lb 3 ( 4%) 66 53-75
Ila 13 (19%) 67 47-78
lIb 3 ( 4%) 65 60-69
Ilia 16 (23%) 65-5 44-82
Illb 11 (16%) 68 59 - 84
Statistics
Median duration ofsurvival was estimated bythe Kaplan -Meier life table method.
Univariate analysis using the log rank test was performed to identify the relation-
ship between variables recorded at diagnosis and duration of survival. These
variables included age, sex, paraprotein class, paraprotein index,7 serum albumin
level, Bence Jones proteinuria, presence of lytic lesions, 132 microglobulin level,
platelet count, serum urea level, serum creatinine level, Durie-Salmon stage and
initial treatment. Cox's proportional hazard regression analysis was then used to
identify those factors that were independently associated with survival. Statistical
significance was taken as p < 0-05. Creatinine and urea values were distributed
in a skewed fashion and were therefore log transformed before analysis Calculat-
ions were performed on an IBM compatible computer using EGRET software.8
The concept of relative risk was used to compare the increased risk of death in
i The Ulster Medical Society, 1993.
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one category compared to a reference category; for continuous variables the
change in risk associated with a one unit change in the variable is expressed.
PATIENTS AND TREATMENT
Two of the 69 patients were excluded from follow-up analysis as they moved
away from the Belfast area. Of the remaining 67, 31 were male (46%) and 36
female (54%). Median age at diagnosis was 66 years for males (range 39-84
years) and 67-5 years for females (range 44-83 years). Twenty-eight patients
(42%) were alive at the end ofthe study. The types ofparaprotein were as shown
in Table 11.
TABLE II
Paraprotein type and relative frequency
Type No
IgAK 5 ( 7%)
IgAX 10 (15%)
IgGK 27 (39%)
IgG X 13 (19%)
K only 5 ( 7%)
A only 8 (12%)
Non-secretor 1 ( 1 %)
The distribution of significant prognostic variables is compared with another
unselected group of patients from Nottingham,9 the lVth and Vth Medical
Research Council myeloma trials and the US South West Oncology Group
Myeloma trial (SWOG 8229)10 and is shown in Table Ill. The unselected
Nottingham group shows a higher proportion of patients with poorerfeatures and
shorter survival than the Belfast City Hospital group. The Belfast City Hospital
and Medical Research Council trial survivals are similar, and the distribution of
variableswithindependent prognostic significance betweenthem wasalsosimilar,
although a higher proportion ofMRC patients were Durie-Salmon stage Ill.
Initial treatment was with melphalan and prednisolone in 22 patients; vincristine,
melphalan, cyclophosphamide and prednisolone in 21; vincristine, adriamycin
and dexamethasone in eight requiring aggressive therapy; melphalan alone in
five; and other combination chemotherapy regimes in 6. Therapy was started if
symptoms were present orthere was evidence ofdisease progression. In general,
aggressive therapy such as VAD (vincristine/adriamycin/dexamethasone) was
reserved for those with advanced disease and was restricted to younger patients.
Thus only one patient aged over 65 years received VAD as initial treatment
and it was used in only one patient with stage I disease (who had spinal cord
compression). Five patients had no treatment, two died within a month of
diagnosis before chemotherapy could be given and three others have survived for
intervalsof 21, 40 and 44 months without chemotherapy. The diagnosis hasbeen
reviewed and confirmed in these 5 patients. Chemotherapy was withheld because
of age or the presence of other illnesses, or lack of evidence of progression of
myeloma. Interferon has been used in some patients during a plateau phase but it
is too early to analyse its effect.
© The Ulster Medical Society, 1993.
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TABLE III
Patient characteristics: Clinical trial and unselected group results
Clinical trials
Haemoglobin (g/dl)
< 7.5
(<8-5)
7-5-10
(8-5-10)
>10
Creatinine (pmol/1)
<130
130-200
> 200
Age (years)
< 50
< 60
< 75
>75
Calcium (mmol/l)
< 2-6
>2-6
Durie-Salmon stage
I
111
SWOG
8229
4
20
76
62
21
17
14
29
50
7
MRC IV
13
19
68
59
22
19
11
31
58
MRCV
11
24
65
57
21
22
10
26
64
Unselected groups
Belfast
City
Nottingham Hospital
(26)
(27)
47
50
20
30
6
55 (50-70)
39 (>70)
69
31
3
19
78
8
5
87
5
9
86
6
(13)
30
(20)
67
69
7
24
5
16
60
19
81
19
37
24
39
15
17
65
Median survival
months
29 (VCP) 29
48
(VMCP -
VBAP)
V = Vincristine
A =Adriamycin
C = Cyclophosphamide
B=Bi CNU
M = Melphalan
P = Prednisolone
*percentage of each group identified by the criteria listed below.
i The Ulster Medical Society, 1993.
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RESULTS
Presenting features
Bone pain was the commonest presenting feature in 34 (51 %) of the patients.
Renal function was impaired at diagnosis in 17 (25%), and 6 (19%) presented
with hvyercalcaemia. Twenty-four Datients (36%) had a haemoalobin level
less than 10 g/dl at diagnosis. Eight
patients (12%), all stage Ia, presented
with features unrelated to myeloma.
Survival data
Fig 1 shows the survival curve for the
study population (median survival 32
months). Formales themedian survival
was 36 months and for females 30
months. The Kaplan Meier survival
estimate at 12 months was 78% (95%
confidence limits 66-86%) and at 36
months 43% (95% confidence limits
30-56%).
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Fig 1. Survival curve for all 67 patients studied.
Fig 2 shows survival by stage. Stage Ill fared worse than stage I (median survivals
18 and 47 months respectively). Fig 3 shows the highly significant reduction in
survival when the platelet count was,< 100 x 109/1.
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Fig 2. Survival curves for67 patients, subdivided
according to stage 1, 11, or 111.
1.00
0.75-
PLs100 X. 0.50-
0.25-
PLTs < 10
0.00
0 10 20 30 40 50 60 70
Tlne (nth)s)
Fig 3. Survival curve for patients, subdivided
according toplatelet count (Pits)<100and >100
(x 109/1).
Table IV analyses the variables thatweresignificant orapproached significance as
prognostic indicators. For categorical variables, the risk of each category relative
to a reference category is shown - the relative risk ofstage II compared to stage I
was 2 6 and for stage III compared with stage I was 2 9. For a continuous
variable the table shows the risk associated with a unit increase in that variable.
For example, because serum creatinine was log10 transformed the relative risk of
2
-4 is that associated with a tenfold increase in creatinine level. A 1 *O g increase
in haemoglobin level is associated with a 21 % reduction in the risk ofdeath.
In the proportional hazard model, stage, age and platelet count were found to
haveindependentprognosticsignificance. Although haemoglobin, creatinineand
©) The Ulster Medical Society, 1993.The Ulster Medical Journal
TABLE IV
Relative risks ofdeath from selectedprognostic variables derivedfrom univariate
(log rank) and multivariate analyses of survival in 67 myeloma patients. 95%
confidence limits in brackets
Univariate results
Relative risk
(95% CL)
1I8 (1*0-3-5)
2*6 (1*0-6*4)
2-9 (1-3-6-7)
Multivariate results
Relative risk
P (95% CL)
0-062 2*7 (1 *4-5-5)
0-024 3-6 (1.4-9.3)
3.7 (1X6-8-9)
Platelets (x 109/1)
< 100 vs > 100
Haemoglobin
(g/dl)
Creatinine
(pmol/l)
(log scale)
Urea (mmol/l)
(log scale)
0.3 (0Q1-0-8)
0*8 (0-6-0-7)
2*4 (1*0-5*8)
3.7 (1*4-9*8)
0-006 0*4 (0-2-0'9)
0*004
0*059
0-015
urea were individually significant they are already considered during staging.
They do not therefore give additional prognostic significance when added to the
model. In contrast to other studies1' serum 132 microglobulin levels (uncorrected
for serum creatinine) were not found to be of prognostic significance but this
measure was often not recorded in those patients who presented with advanced
disease.
EARLY DEATHS
Eight patients died within six months of diagnosis. Ofthese, three were Stage lIa,
two Stage Illa and three Stage Illb. One patient refused further admission to
hospital and died at home two months after diagnosis. Three died of documented
sepsis which was also strongly suspected as the cause of death of two others. One
patient died ofcomplications of renal failure and hypercalcaemia, and one from a
probable pulmonary embolus. The number of hospital admissions for the 39
deceased patients ranged from 1 to 21 but with a median of 2 admissions during
the course of their illness. The percentage of total time in hospital from diagnosis
to death ranged from 0 5% to 100%, with a median 6-7 %. Fifteen of "the
patients who died received at least one course of radiotherapy for palliation of
bone pain during the course of their illness.
The Ulster Medical Society, 1993.
Variable
Age
> 70 yr
vs < 70 yrs
Stage
11 vs I
111 vs I
p
0*005
0*003
0-037
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DISCUSSION
In general the diagnosis of myeloma is straightforward, but difficulties can arise
during the early stages. Table V shows the minimal criteria for the diagnosis of
myeloma from several centres.5"213'4 It is possible for example to meet the
criteria for the diagnosis of myeloma and yet not be eligible for entry into the
MRC V myeloma trial. Only about 15% ofpatients with myeloma are entered into
trials co-ordinated by the MRC.3
TABLE V
Criteria for diagnosis ofmyeloma
Source
Chronic leukaemia
myeloma
task force10
Hjorth5
RA Kyle II
Maconduit12
MRC V
myeloma trial4
Belfast City
Hospital
A
% Plasma cells
in bone marrow
> 5% in marrow
aspirate or
other tissue
>10%
> 10% abnormal
immature plasma
cells or histological
proof of
extramedullary
plasmacytoma
>15% or
infiltrates in
biopsy
>20%
or evidence of
monoclonality
if<20%
> 5% in marrow
aspirate
B
Paraprotein
level
Monoclonal
globulin
IgG >30 g/l
or
IgG>20 g/l
and/or
BJ>lg/l
M protein in
serum
(usually'>30 g/l
or in urine
Associated
M component
Band in
blood or urine
Monoclonal
globulin
C
Osteolytic
lesions
Minimal criteria
for myeloma
Osteolytic B + A
bone lesions or
B+C
Osteolytic A + B
bone lesions or
A+C
Osteolytic A and usual
lesions clinical features
of myeloma
and either B or C
Not required A + B
Definite Eligible for entry
lytic lesions if any two of
ABC
Lytic lesions B+A or B+C
The present study, although encompassing a relatively small number of patients,
was comprehensive in that it included all patients with myeloma (except two)
diagnosed during a five year period. Comparison with the Nottingham unselected
group9 shows a slightly longer survival, which could be explained by the higher
proportion of patients in the Nottingham study with poor prognostic features.
Survival resultsfrom trialscannotbecompared directlywiththosefromunselected
groups becauseoftheexclusionofpatientswithunfavourable prognosticfeatures.
Such exclusions have been shown to have significant effects on survival results
from trials.5 Our results approximate to those ofthe MRC trials but it is not clear
whether the patient populations aresimilar. Table Ill showsthatthe distribution of
variables of individual prognostic significance is similar in trial patients and in our
series, even though 19% of our patients are aged over 75. The Salmon-Durie
© The Ulster Medical Society, 1993.
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staging system suggests that a higher proportion of the MRC trial patients had
advanced disease. Durie himself has questioned the wisdom of a staging system
which gives undue importance to the presence of lytic lesions, which were demon -
strated in 70% of trial patients and yet had limited prognostic significance on their
own.'0 Differences in the interpretation of radiographic findings may be important
as this is more subjective than the interpretation of the other paramaters used in
staging, which could cause an apparent difference between our series and trial
patients as judged by the staging system.
Eight of our patients had myeloma diagnosed at an early stage as an incidental
finding. They were given various chemotherapeutic regimes; one died at 19
months from a ruptured abdominal aneurysm, the other seven remain alive and
well at follow-up periods ranging from 12 to 70 months (median 40 months).
While there have been no trials showing survival benefit from early treatment of
myeloma, the experience with this small group of eight patients is encouraging. In
the absence of a specific indication (such as bone plasmacytoma) such treatment
remains a difficult decision.
In 1956 five year survival figures for myeloma averaged 5-6%.15 There was
an improvement following the introduction of melphalan and prednisolone about
1965. The recognition of the importance of infection and its improved treatment
has also led to improved survival. There has been little further improvement
despite the recent use of additional alkylating agents and anthracyclines. The
VAD (vincristine, adriamycin, dexamethasone) regimen is very effective in
relapsed and refractory myeloma but it has not been shown to improve survival
when used in previously untreated patients.16' 17 Indeed there is some evidence
that the most important part of the VAD regimen is dexamethasone,18 although
the other agents contribute to its effectiveness.
Marrow ablative therapy with haemopoietic stem cell support has been shown
recently to produce complete remission rates of 20-30%.19, 20,21, 22 Allogeneic
bone marrow transplantation (from HLA matched donors) has been used in
myeloma patients under 55 years of age. Of the typical population with myeloma,
75 % would be excluded on the basis of age with a further reduction due to
lack of HLA matched siblings. Gahrton22 reported a mortality of 40% from
treatment- related complications, which seems unacceptably high especially
as most survivors ultimately relapse. Two-thirds of myeloma patients could
be eligible for autologous bone marrow transplantation (using their own bone
marrow) as mortality from this procedure has been shown not to increase up to
age70.21 Recently it has been demonstrated that peripheral blood stem cells may
be harvested following the use of chemotherapy and the cytokine granulocyte-
colony stimulating factor (G - CSF).23 The patient's bone marrow may be
reconstituted using these peripheral blood stem cells avoiding the use of auto -
logous marrow which may be contaminated with myeloma cells. The technique is
limited as the yield of peripheral blood stem cells is much poorer in patients who
have been heavily pretreated with chemotherapy or radiotherapy. The implication
of these reports is that stem cell damage due to prolonged alkylating therapy
should be avoided in potential candidates for autologous transplantation. Early
assessment of suitability for such a procedure should be undertaken, ideally at
the time of diagnosis, and peripheral blood stem cell harvest undertaken in the
early stages of treatment, as is now the practice at this hospital.
© The Ulster Medical Society, 1993.
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Even though overall survival in myeloma may not have improved dramatically
since the introduction of melphalan, much can now be done to palliate this
devastating illness. The majority of patients have good quality survival and most
are managed as outpatients. Recent developments such as the use of interferon
to prolong plateau phase and the use of G -CSF to harvest peripheral blood stem
cells and increase the safety of marrow transplantation suggest that further
improvement in survival may now be obtainable.
We thank DrC Patterson for his invaluable statistical advice, and Miss C Shiels and Mrs J Creighton for
careful typing of the manuscript.
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